Streetbeat News

Products Services

PROC

Procaps Group's new CEO, Jose Vieira, issued a letter to shareholders outlining his immediate focus on strengthening the company's financial position and cash management. He emphasized a commitment to transparency, innovation, and collaboration, aiming for consistent growth and profitability. Vieira plans to implement immediate actions to improve the financial situation in the short term and is developing a clear strategy for sustainable growth.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:53 pm

MGRX

Mangoceuticals, Inc. (NASDAQ:MGRX), also known as MangoRx, is launching 'PRIME', an oral testosterone replacement therapy powered by Kyzatrex. The Dallas-based telemedicine company is offering 2 months of free 'PRIME' to the first 1,000 male subscribers. This promotion is part of a broader marketing strategy, including a marquee sponsorship with Barstool Sports. PRIME is one of only three FDA-approved oral TRT treatments, promising enhanced vitality, mood, cognition, and physical performance. It will be priced at $199/month, with a 10% discount for subscribers of other MangoRx products.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:52 pm

RVSN

Rail Vision Ltd. (NASDAQ:RVSN), an Israeli technology company, announced receiving a patent approval from the Indian Patent Office for a railway collision avoidance system. This patent, also approved in the US and Japan, covers advanced vision sensor technology for detecting and identifying railway obstacles in real time. The system, which incorporates AI and big data, is seen as a significant advancement for railway safety and operational efficiency, especially in India's vast railway network.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:50 pm

BRTX

CDIO

FDMT

4D Molecular Therapeutics (FDMT) presented positive interim data from its Phase 2 PRISM trial for 4D-150 in Wet AMD, showing good tolerability and clinical activity. BioRestorative Therapies (BRTX) shared preliminary data from its Phase 2 trial of BRTX-100 in chronic lumbar disc disease at the Orthopaedic Research Society 2024 Annual Meeting. Cardio Diagnostics (CDIO) announced its AI-driven epigenetic-genetic heart disease tests will be offered at Houston's resTOR Longevity Clinic.

Portfolio Pulse from ryanfaloona@benzinga.com

February 05, 2024 | 1:49 pm

CAT

Caterpillar's CEO reported in a conference call that overall demand for the company's products and services remains healthy across most end markets. However, there is some softening in economic conditions in the Asia Pacific region, excluding China.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:49 pm

OMQS

OMNIQ Corp. (NASDAQ:OMQS) has acquired CodeBlocks Ltd, a leading fintech software developer, for approximately $1.275M. This acquisition enhances OMNIQ's fintech offerings in self-service kiosks, credit card payment systems, and point-of-sale technologies. CodeBlocks' proprietary software, with over 80,000 deployments, is expected to bring immediate cost savings and market share expansion opportunities to OMNIQ.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:46 pm

CTLT

NVO

Novo Nordisk A/S (NYSE:NVO) has acquired three fill-finish sites from Novo Holdings A/S for $11 billion, as part of a deal where Novo Holdings acquires Catalent, Inc. (NYSE:CTLT). This acquisition aims to expand Novo Nordisk's manufacturing capacity for diabetes and obesity treatments, with the sites located in Italy, Belgium, and Indiana. The deal, mainly debt-financed, is expected to boost Novo Nordisk's filling capacity from 2026 and aligns with its strategy to enhance treatment accessibility for diabetes and obesity.

Portfolio Pulse from Benzinga Neuro

February 05, 2024 | 1:40 pm

CDIO

Cardio Diagnostics Holdings announced that its resTOR Longevity Clinic will be the first nationwide to offer the company's AI-driven epigenetic-genetic tests for cardiovascular disease. These tests, which are blood-based, aim to provide advanced insights into heart disease risks.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:38 pm

AAPL

Apple Inc.'s (NASDAQ:AAPL) Vision Pro headset has proven to be more durable than expected in recent tests, surviving impacts and drops with minimal damage. Despite its high price of $3,499, the device's resilience could alleviate consumer concerns about its longevity and justify its cost. The durability, combined with its potential to replace devices like the iPad, may positively influence its market reception and future sales.

Portfolio Pulse from Ananya Gairola

February 05, 2024 | 1:37 pm

LLY

Eli Lilly (NYSE:LLY) is anticipated to release its Q4 earnings on Feb. 6, 2024, with expected earnings of $2.19 per share and revenue of $8.93 billion, up from the previous year. The company is in talks with the German government to lift a ban on weight-loss treatment coverage. Eli Lilly offers a 0.78% annual dividend yield, equating to $1.30 per share quarterly. To earn $500 monthly from dividends, an investment of approximately $770,468 is required. LLY shares rose 1.1% to close at $667.65 recently.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 1:36 pm